Last Updated: September 23, 2026
Sublingual vs. Subcutaneous Ketamine: What's the Difference?
Sublingual and subcutaneous ketamine deliver the same medicine two ways: sublingual is a needle-free tablet absorbed through the lining of the mouth, and subcutaneous is a small injection just under the skin that acts faster and absorbs more predictably. The routes differ in onset and absorption, not in how well treatment works, and both are prescribed at home under clinician supervision. Mindbloom is the only at-home provider that offers both, so the choice is about which route fits you rather than which one works better. This guide covers how each route works, what the research shows across both, and how to choose the one that suits you.
Key takeaways
- Sublingual is a needle-free tablet with effects in about 10 to 15 minutes; subcutaneous is a small injection acting in about 5 minutes.
- Sublingual ketamine absorbs about 29% of a dose and subcutaneous absorbs about 90%, but that gap sets the milligram dose prescribed, not how well treatment works.
- Higher bioavailability does not mean better outcomes: Mindbloom's published depression response rates were 56.4% sublingual and 56.6% subcutaneous despite a roughly threefold difference in absorption.
- Across routes, serious adverse events occur in roughly 0.1% of people treated with sub-anesthetic ketamine.
- A licensed clinician helps choose your route, and Mindbloom is the only at-home provider offering both tablets and injectables.
What's the Difference Between Sublingual and Subcutaneous Ketamine?
Both are the same medicine given by two different delivery methods. Sublingual is a tablet held in the mouth and absorbed through the oral lining, so it is needle-free, gentler in onset, and lower in bioavailability. Subcutaneous is a small injection just under the skin, so it acts faster and is absorbed more fully and consistently.
Bioavailability is the share of a dose that actually reaches your bloodstream. It shapes onset and how the dose is set, not how well treatment works: a route that absorbs less is simply prescribed at a higher milligram amount to reach the same therapeutic window. Mindbloom's own guide to comparing tablets and injectables walks through the same head-to-head.
Here is how the two routes line up at a glance.
Here is how each route actually works.
How Sublingual Ketamine Works
Sublingual ketamine is absorbed through the lining of your mouth rather than swallowed. "Sublingual" means under and against the tongue and cheek, where blood vessels sit close to the surface.
With Mindbloom Tablets, you hold the tablet in your mouth for about 7 minutes, then spit it out. Some medicine is still swallowed, and the liver breaks down part of it before it reaches your blood. Because of this first-pass effect, the sublingual bioavailability is near 29%, reported at 29% (27, 31%) in pharmacokinetic research1.
Lower bioavailability does not mean weaker treatment. Your clinician sets the dose to the route, so absorption is planned into your care. Mindbloom's guide covers sublingual dosing and absorption in more detail.
What a Sublingual Session Feels Like
A sublingual session is needle-free and tends to build gradually. With Mindbloom Tablets, effects typically begin in about 10 to 15 minutes.
Some people find session intensity varies a little more than with an injection. Many describe the experience as gentle, which can suit anyone new to ketamine therapy or wary of needles.
How Subcutaneous Ketamine Works
Subcutaneous ketamine is delivered by a small injection into the fatty tissue just under your skin. "Subcutaneous" simply means beneath the skin, the same layer used for insulin. Subcutaneous is the least widely available of the injectable routes, since facility-based clinics generally deliver ketamine by IV or intramuscular injection, and Mindbloom is currently the only at-home provider offering subcutaneous administration under clinician supervision.
This route skips the digestive system, so more of the medicine reaches your blood and absorption is more predictable. Injectable ketamine reaches a high bioavailability: a medical reference notes the injection bioavailability around 93% for the intramuscular route, with peak plasma levels within 5 to 30 minutes2. Subcutaneous delivery sits close to intramuscular and intravenous administration. Ketamine's elimination half-life is about two to three hours regardless of route2, so tablets and injectables clear the body on a similar timeline. The routes differ in how quickly the medicine arrives, not in the drug itself, and higher absorption is planned into care by setting the dose to the route rather than making the treatment stronger.
A systematic review of subcutaneous ketamine research describes the route as more convenient, cheaper, and less complex, and suggests it can be as effective as, and possibly safer than, IV administration3. You can also see how at-home subcutaneous injectables are delivered on Mindbloom's product page.
What a Subcutaneous Session Feels Like
A subcutaneous session starts faster and feels more consistent. With Mindbloom Injectables, a tiny insulin needle delivers the medicine into the abdomen, and effects typically begin in about 5 minutes.
Among Mindbloom clients who have tried both, many report finding injectables easier and preferring the steadier pace. Preference is personal, though, and does not reflect a difference in outcomes between the routes.
Comparing Effectiveness: What the Research Shows
Neither route is clearly more effective than the other, and the difference in bioavailability does not translate into better outcomes. The clearest evidence comes from Mindbloom itself, the only at-home provider to have published peer-reviewed outcomes on both routes: sublingual depression response was 56.4% (Mathai et al. 2024) and subcutaneous response was 56.6% (Parks et al. 2026), nearly identical despite a roughly threefold difference in how much drug each route delivers. The figures below come from separate studies with different cohorts and course lengths, so this is a descriptive comparison of two real-world datasets rather than a head-to-head.
Mindbloom's sublingual evidence spans two peer-reviewed studies. In its first published study, nearly 9 in 10 clients (89%) reported improvement (Hull et al. 2022)⁴. In its largest, an analysis of 11,441 clients, 61.4% saw clinically significant change and 56.4% met response criteria on the PHQ-9 (Mathai et al. 2024)⁵. Individual results may vary.
Mindbloom's subcutaneous study analyzed 3,041 clients and found that, among those treated for depression, 81.8% saw clinically meaningful improvement, 56.6% responded, and 27.7% reached remission on the PHQ-9 (Parks et al. 2026)⁶. Individual results may vary.
Both routes also land in the range reported for in-clinic IV ketamine, which points to the supervised, guided program, rather than the delivery route, as what drives results. Ketamine's biological effects are set by the prescribed dose, not by which route delivers it, so a clinician matches the dose to the route to reach the same therapeutic window. This pattern is not limited to one provider: an independent at-home study found sublingual ketamine to be a safe and effective treatment for treatment-resistant depression and anxiety (Hassan et al. 2022)⁷.
Side Effects and Safety by Route
Most side effects of ketamine therapy are mild and short-lived, and serious events are rare across both routes. Side effects are possible outcomes, not guaranteed experiences.
When side effects occur, they can include nausea, dizziness, and a temporary rise in blood pressure. Some people notice a rise in blood pressure because ketamine briefly stimulates the cardiovascular system. Dissociation, a sense of feeling separate from your body, is a known and often therapeutically meaningful part of the experience within a supervised setting.
Each route can add a few route-specific effects:
- Sublingual: a bitter taste or other mouth-related effects while holding the tablet.
- Subcutaneous: mild injection-site reactions, such as brief redness where the needle enters.
In Mindbloom's sublingual study, side effects occurred in about 4 to 5% of sessions. In its subcutaneous study, side effects were reported in about 2.8 to 3.2% per check-in.
Serious adverse events, meaning unexpected and serious medical events, are a different category. An independent systematic review found serious events are rare, at approximately 0.1% of individuals treated with sub-anesthetic ketamine7. Mindbloom reports serious adverse event rates of 0.05% for its sublingual route and 0.08% for its subcutaneous route. Individual results may vary.
Safety also comes from how sessions are run. Mindbloom requires a peer treatment monitor, a responsible adult, to stay with you during every session and the post-session transition.
How to Choose the Right Route for You
The right route depends on your comfort, your goals, and your provider's guidance, not on bioavailability alone. Both routes deliver the same medicine inside the same supported program.
A few factors usually guide the decision:
- Comfort with needles: Sublingual is needle-free and an approachable entry point. Subcutaneous involves a small injection under the skin.
- Pace and consistency: Subcutaneous begins faster and feels more consistent, which some people prefer.
- Stomach sensitivity or taste: Because subcutaneous injectables bypass the digestive tract, they can suit people who dislike the tablet's taste or who are prone to nausea or stomach upset. Sublingual tablets remain the needle-free option for anyone who prefers to avoid injections.
- Past experience: If earlier tablet sessions felt uneven, an injection may offer a steadier pace, and either route can be adjusted with your clinician.
At Mindbloom, a licensed clinician helps determine your route during your consult, and you can switch routes over time as your needs change. Higher absorption changes onset and dosing, but bioavailability does not drive results on its own.
Route does not change the price either. Mindbloom's program cost is set by length, with new-client sessions running about $165 to $215 depending on the program you choose. Cost is not a deciding factor between tablets and injectables.
How Sublingual and Subcutaneous Compare to Other Ketamine Routes
Sublingual and subcutaneous are two of several ways to take ketamine. Each route suits different needs, and no single route is best for everyone.
IV ketamine is given in a clinic, reaches close to 100% bioavailability, and acts almost immediately. Intramuscular injection is also clinic-based, with bioavailability around 93%. Oral ketamine has the lowest absorption of these routes. As with the at-home routes, these differences set the milligram dose each route requires; they do not rank the routes by how well treatment works. You can compare these other ketamine delivery methods in Mindbloom's overview.
Which Ketamine Routes Are FDA-Approved?
Esketamine, sold as Spravato, is the only FDA-approved ketamine-derived medicine, given as an intranasal spray in a clinic. The FDA-approved esketamine nasal spray label reports a mean absolute bioavailability of approximately 48% following nasal spray administration8.
Sublingual and subcutaneous ketamine are prescribed off-label by licensed clinicians. Off-label prescribing is common and legal, and the AHRQ reports that about one in five prescriptions written today are for off-label use9.
In supervised, sub-anesthetic therapeutic programs, the risk of misuse is low. Ketamine is a Schedule III controlled substance, and licensed providers prescribe it within that framework. When ketamine is compounded, it is prepared by licensed compounding pharmacies, a regulated and common part of US healthcare.
Two Routes, One Goal: Personalized Ketamine Care
Sublingual and subcutaneous ketamine deliver the same medicine two ways, and both produce closely comparable results inside supervised, guided programs, on par with what in-clinic IV ketamine reports. Two routes with very different absorption landing in the same place is the clearest sign that the supervised program, not the delivery method, is what drives outcomes. The best route is an individualized medical decision, made with a licensed clinician who knows your history and goals.
Mindbloom is the only at-home provider offering both tablets and injectables, so you can start with the route that fits and adjust over time. Talk with a licensed clinician about which route suits you. Book My Breakthrough.
Frequently asked questions
Is Sublingual or Subcutaneous Ketamine More Effective?
Neither route is clearly more effective. Mindbloom has published peer-reviewed outcomes on both a sublingual route that absorbs roughly a third of a dose and a subcutaneous route that absorbs far more, and depression response rates were 56.4% and 56.6% respectively, so a large difference in absorption produced almost no difference in outcome.
Which Route Works Faster?
Subcutaneous ketamine usually acts faster, with effects beginning in about 5 minutes, compared with about 10 to 15 minutes for sublingual tablets. Faster onset does not mean the antidepressant benefits arrive sooner, though. On both routes, improvement builds over a course of sessions.
Is It Safe to Do Subcutaneous Ketamine at Home?
At-home subcutaneous ketamine is delivered within a clinician-supervised program. At Mindbloom, a licensed clinician oversees your care and a peer treatment monitor, a responsible adult, stays with you through every session and the post-session transition. Serious adverse events are rare across routes, at roughly 0.1% with sub-anesthetic ketamine.
Does Mindbloom Still Offer Sublingual Ketamine Tablets?
Yes. Mindbloom offers both sublingual tablets and subcutaneous injectables, and your route is chosen with a licensed clinician.
Can I Switch From Tablets to Injections?
Yes. At Mindbloom, you can switch routes over time as your needs and preferences change, with provider guidance.
Is Sublingual or Subcutaneous Ketamine FDA-Approved?
Neither is FDA-approved, and both are prescribed off-label by licensed clinicians. Esketamine nasal spray is the only FDA-approved ketamine-derived medicine.
Does the Route Change How Much Treatment Costs?
No. Mindbloom's pricing is based on program length, not the route, so tablets and injectables cost the same within a given program.
Mindbloom Treatment
See what might be possible with clinician-guided, at-home ketamine therapy. New client programs start at $165 per session.
Authors
